Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options

Martin G. Sanda, Jeffrey A Cadeddu, Erin Kirkby, Ronald C. Chen, Tony Crispino, Joann Fontanarosa, Stephen J. Freedland, Kirsten Greene, Laurence H. Klotz, Danil V. Makarov, Joel B. Nelson, George Rodrigues, Howard M. Sandler, Mary Ellen Taplin, Jonathan R. Treadwell

Research output: Contribution to journalArticle

87 Scopus citations

Abstract

Purpose: This guideline is structured to provide a clinical framework stratified by cancer severity to facilitate care decisions and guide the specifics of implementing the selected management options. The summary presented herein represents Part II of the two-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline discussing risk stratification and care options by cancer severity. Please refer to Part I for discussion of specific care options and outcome expectations and management. Materials and Methods: The systematic review utilized in the creation of this guideline was completed by the Agency for Healthcare Research and Quality and through additional supplementation by ECRI Institute. This review included articles published between January 2007 and March 2014 with an update search conducted through August 2016. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. Additional information is provided as Clinical Principles and Expert Opinions (table 2 in supplementary unabridged guideline, http://jurology.com/). Results: The AUA (American Urological Association), ASTRO, and SUO (Society of Urologic Oncology) formulated an evidence-based guideline based on a risk stratified clinical framework for the management of localized prostate cancer. Conclusions: This guideline attempts to improve a clinician's ability to treat patients diagnosed with localized prostate cancer, but higher quality evidence in future trials will be essential to improve the level of care for these patients. In all cases, patient preferences should be considered when choosing a management strategy.

Original languageEnglish (US)
Pages (from-to)990-997
Number of pages8
JournalJournal of Urology
Volume199
Issue number4
DOIs
StatePublished - Apr 1 2018

Keywords

  • guideline
  • prostate
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options'. Together they form a unique fingerprint.

  • Cite this

    Sanda, M. G., Cadeddu, J. A., Kirkby, E., Chen, R. C., Crispino, T., Fontanarosa, J., Freedland, S. J., Greene, K., Klotz, L. H., Makarov, D. V., Nelson, J. B., Rodrigues, G., Sandler, H. M., Taplin, M. E., & Treadwell, J. R. (2018). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options. Journal of Urology, 199(4), 990-997. https://doi.org/10.1016/j.juro.2018.01.002